REGENERON PHARMACEUTICALS (REGN) Stock News
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
REGN Latest News, Press Relases and Analysis
Discover which S&P500 stocks are making waves on Monday.
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.
These S&P500 stocks are gapping in today's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: EXAS
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
Why AbbVie Inc. (ABBV) is Among the Best Stocks That Will Always Grow
We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over the […]
Regeneron partners with Fujifilm to broaden manufacturing capacity
Regeneron is currently expanding its Tarrytown campus with an investment of nearly $3.6bn.
Mentions: TSLA
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: GILD
Regeneron Inks Deal With Fujifilm Diosynth Biotechnologies To Increase Manufacturing In US: Retail’s Optimistic
The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years.
Roche, answering tariff threat, pledges $50B to US drug production
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S.
Regeneron to invest over $3 billion to boost US manufacturing
Major U.S. drugmakers, including Eli Lilly and Johnson & Johnson, have recently announced additional investments in their U.S. production as they prepare to deal with potential drug import duties from President Donald Trump's administration. Last week, the U.S. opened a national security investigation into pharmaceutical companies to show why the country needs tariffs to boost domestic manufacturing. Under the terms of the deal, Tokyo-based Fujifilm Diosynth's facility in Holly Springs, North Carolina will manufacture and supply drug products for Regeneron's biologic medicines for a span of 10 years.
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic...
Regeneron Inks $3 Billion Fujifilm Deal to Bolster US Drugmaking
Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms over the nation’s drug supply.
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: ...
Is Thermo Fisher Scientific Inc. (TMO) the Best American Dividend Stock to Buy According to Analysts?
We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by delivering consistent and solid returns. During periods of […]
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Mentions: SNY
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than...
Why Transocean Ltd. (RIG) is Skyrocketing?
We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Transocean Ltd. (NYSE:RIG) stands against other other firms that ended the week strong. The stock market ended the shortened trading week mixed, with two of the major indices […]
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period –...
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year. Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent.